Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 4404Urinary Bladder Neoplasms 1080Carcinoma, Renal Cell 1042Kidney Neoplasms 568Breast Neoplasms 454Neoplasms 406Carcinoma, Transitional Cell 301Neoplasm Metastasis 251Lung Neoplasms 243Testicular Neoplasms 202Melanoma 196Colorectal Neoplasms 194Ovarian Neoplasms 165Carcinoma, Non-Small-Cell Lung 150Non-Muscle Invasive Bladder Neoplasms 136Sarcoma 135Pancreatic Neoplasms 125Colonic Neoplasms 121Head and Neck Neoplasms 117Uterine Cervical Neoplasms 116Wilms Tumor 108Recurrence 106Motor Activity 100Urologic Neoplasms 90Stomach Neoplasms 89Neuroblastoma 88Disease 85Multiple Myeloma 83Carcinoma, Hepatocellular 81Adenocarcinoma 79

Interventions

proxalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Neoadjuvant Therapy \High Risk Prostate Cancer × Genitourinary × Clear all
NCT05076851 2021-10-13

Neoadjuvant Therapy With Proxalutamide Combined With Androgen Deprivation Therapy(ADT)for High Risk Prostate Cancer

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Unknown
2 enrolled
Genitourinary

Neoadjuvant Therapy \High Risk Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡